Suppr超能文献

口服钴胺素有效治疗钴胺素缺乏症。

Effective treatment of cobalamin deficiency with oral cobalamin.

作者信息

Kuzminski A M, Del Giacco E J, Allen R H, Stabler S P, Lindenbaum J

机构信息

Division of General Internal Medicine, Bassett Healthcare, Cooperstown, NY, USA.

出版信息

Blood. 1998 Aug 15;92(4):1191-8.

PMID:9694707
Abstract

Because cobalamin deficiency is routinely treated with parenteral cobalamin, we investigated the efficacy of oral therapy. We randomly assigned 38 newly diagnosed cobalamin deficient patients to receive cyanocobalamin as either 1 mg intramuscularly on days 1, 3, 7, 10, 14, 21, 30, 60, and 90 or 2 mg orally on a daily basis for 120 days. Therapeutic effectiveness was evaluated by measuring hematologic and neurologic improvement and changes in serum levels of cobalamin (normal, 200 to 900 pg/mL) methylmalonic acid (normal, 73 to 271 nmol/L), and homocysteine (normal, 5.1 to 13.9 micromol/L). Five patients were subsequently found to have folate deficiency, which left 18 evaluable patients in the oral group and 15 in the parenteral group. Correction of hematologic and neurologic abnormalities was prompt and indistinguishable between the 2 groups. The mean pretreatment values for serum cobalamin, methylmalonic acid, and homocysteine were, respectively, 93 pg/mL, 3,850 nmol/L, and 37. 2 micromol/L in the oral group and 95 pg/mL, 3,630 nmol/L, and 40.0 micromol/L in the parenteral therapy group. After 4 months of therapy, the respective mean values were 1,005 pg/mL, 169 nmol/L, and 10.6 micromol/L in the oral group and 325 pg/mL, 265 nmol/L, and 12.2 micromol/L in the parenteral group. The higher serum cobalamin and lower serum methylmalonic acid levels at 4 months posttreatment in the oral group versus the parenteral group were significant, with P < .0005 and P < .05, respectively. In cobalamin deficiency, 2 mg of cyanocobalamin administered orally on a daily basis was as effective as 1 mg administered intramuscularly on a monthly basis and may be superior.

摘要

由于维生素B12缺乏症通常采用肠胃外给予维生素B12的方式进行治疗,我们对口服疗法的疗效进行了研究。我们将38例新诊断为维生素B12缺乏的患者随机分组,一组在第1、3、7、10、14、21、30、60和90天接受1毫克氰钴胺肌肉注射,另一组每天口服2毫克氰钴胺,持续120天。通过测量血液学和神经学的改善情况以及血清中维生素B12(正常范围为200至900皮克/毫升)、甲基丙二酸(正常范围为73至271纳摩尔/升)和同型半胱氨酸(正常范围为5.1至13.9微摩尔/升)水平的变化来评估治疗效果。随后发现5例患者存在叶酸缺乏,这使得口服组有18例可评估患者,肠胃外注射组有15例可评估患者。两组血液学和神经学异常的纠正迅速且无差异。口服组血清维生素B12、甲基丙二酸和同型半胱氨酸的治疗前平均水平分别为93皮克/毫升、3850纳摩尔/升和37.2微摩尔/升,肠胃外注射治疗组分别为95皮克/毫升、3630纳摩尔/升和40.0微摩尔/升。治疗4个月后,口服组相应的平均值分别为1005皮克/毫升、169纳摩尔/升和10.6微摩尔/升,肠胃外注射组分别为325皮克/毫升、265纳摩尔/升和12.2微摩尔/升。口服组治疗后4个月时血清维生素B12水平较高且血清甲基丙二酸水平较低,与肠胃外注射组相比差异有统计学意义,P值分别<0.0005和<0.05。在维生素B12缺乏症中,每天口服2毫克氰钴胺与每月肌肉注射1毫克氰钴胺效果相同,且可能更优。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验